Quantum-Si Announces New Executive Team Members to Accelerate the Evolution of the Company into a Leading Proteomic Tool Provider
Quantum-Si (Nasdaq: QSI), a protein sequencing company, has announced key executive appointments to drive its evolution as a leading proteomic tool provider. Todd Bennett will join as Chief Commercial Officer on September 16, 2024, bringing over 30 years of commercial leadership experience in life science tools and diagnostics. John Vieceli, Ph.D. has been named Chief Product Officer, leveraging his expertise in product development and launch from leading life sciences companies. Lindsay Thompson has been promoted to Chief Human Resources Officer, recognizing her contributions to the company's culture and talent management.
These strategic appointments aim to accelerate the global adoption of Quantum-Si's Platinum® technology and enhance product development and delivery. The company is focusing on integrating all activities from product development to customer delivery under the new Chief Product Officer role. Grace Johnston, Ph.D., has resigned as Chief Commercial Officer and will provide transitional support until September 6, 2024.
Quantum-Si (Nasdaq: QSI), un'azienda specializzata nella sequenziazione delle proteine, ha annunciato importanti nomine esecutive per guidare la sua evoluzione come fornitore di strumenti proteomici di riferimento. Todd Bennett assumerà il ruolo di Chief Commercial Officer il 16 settembre 2024, portando con sé oltre 30 anni di esperienza nella leadership commerciale nel settore degli strumenti per le scienze della vita e della diagnostica. John Vieceli, Ph.D. è stato nominato Chief Product Officer, sfruttando la sua esperienza nello sviluppo e nel lancio di prodotti presso importanti aziende nelle scienze della vita. Lindsay Thompson è stata promossa a Chief Human Resources Officer, riconoscendo il suo contributo alla cultura aziendale e alla gestione dei talenti.
Queste nomine strategiche mirano ad accelerare l'adozione globale della tecnologia Platinum® di Quantum-Si e a migliorare lo sviluppo e la consegna dei prodotti. L'azienda si sta concentrando sull'integrazione di tutte le attività, dallo sviluppo del prodotto alla consegna al cliente, sotto il nuovo ruolo di Chief Product Officer. Grace Johnston, Ph.D., ha rassegnato le dimissioni da Chief Commercial Officer e fornirà supporto transitorio fino al 6 settembre 2024.
Quantum-Si (Nasdaq: QSI), una empresa de secuenciación de proteínas, ha anunciado nombramientos clave en su equipo ejecutivo para impulsar su evolución como proveedor líder de herramientas proteómicas. Todd Bennett se unirá como Director Comercial el 16 de septiembre de 2024, aportando más de 30 años de experiencia en liderazgo comercial en herramientas para ciencias de la vida y diagnósticos. John Vieceli, Ph.D. ha sido nombrado Director de Producto, aprovechando su experiencia en el desarrollo y lanzamiento de productos en destacadas empresas de ciencias biológicas. Lindsay Thompson ha sido ascendida a Directora de Recursos Humanos, reconociendo sus contribuciones a la cultura de la empresa y la gestión del talento.
Estos nombramientos estratégicos tienen como objetivo acelerar la adopción global de la tecnología Platinum® de Quantum-Si y mejorar el desarrollo y la entrega de productos. La empresa se está enfocando en integrar todas las actividades desde el desarrollo del producto hasta la entrega al cliente bajo el nuevo rol de Director de Producto. Grace Johnston, Ph.D., ha renunciado como Directora Comercial y proporcionará apoyo transitorio hasta el 6 de septiembre de 2024.
퀀텀-시(Quantum-Si)(나스닥: QSI), 단백질 서열 분석 회사가 주요 경영진 임명을 발표하여 주요 단백질 도구 제공업체로의 발전을 추진하고 있습니다. 토드 베넷(Todd Bennett)가 2024년 9월 16일 최고 상업 책임자(Chief Commercial Officer)로 합류하며, 생명 과학 도구 및 진단 분야에서 30년 이상의 상업적 리더십 경험을 가지고 있습니다. 존 비셀리(John Vieceli), Ph.D.는 제품 개발 및 출시 전문성을 활용하여 최고 제품 책임자(Chief Product Officer)로 지명되었습니다. 린지 톰슨(Lindsay Thompson)은 회사의 문화와 인재 관리에 대한 기여를 인정받아 최고 인사 책임자(Chief Human Resources Officer)로 승진하였습니다.
이러한 전략적 임명은 퀀텀-시의 Platinum® 기술의 글로벌 채택을 가속화하고 제품 개발 및 공급을 향상시키는 것을 목표로 합니다. 회사는 새로운 최고 제품 책임자 역할 하에 제품 개발부터 고객 배송까지 모든 활동을 통합하는 데 집중하고 있습니다. 그레이스 존스턴(Grace Johnston), Ph.D.는 최고 상업 책임자로 사임하였으며, 2024년 9월 6일까지 전환 지원을 제공할 예정입니다.
Quantum-Si (Nasdaq: QSI), une entreprise spécialisée dans le séquençage des protéines, a annoncé des nominations clés au sein de son équipe dirigeante pour orienter son évolution en tant que fournisseur d'outils protéomiques de premier plan. Todd Bennett rejoindra l'entreprise en tant que Directeur Commercial le 16 septembre 2024, apportant plus de 30 ans d'expérience dans le leadership commercial dans le domaine des outils de sciences de la vie et des diagnostics. John Vieceli, Ph.D. a été nommé Directeur Produit, tirant parti de son expertise en développement et lancement de produits dans des entreprises de sciences de la vie de premier plan. Lindsay Thompson a été promue Directrice des Ressources Humaines, reconnaissant ses contributions à la culture de l'entreprise et à la gestion des talents.
Ces nominations stratégiques visent à accélérer l'adoption mondiale de la technologie Platinum® de Quantum-Si et à améliorer le développement et la livraison de produits. L'entreprise se concentre sur l'intégration de toutes les activités, allant du développement de produits à la livraison au client, sous le nouveau rôle de Directeur Produit. Grace Johnston, Ph.D., a démissionné de son poste de Directeur Commercial et fournira un soutien transitoire jusqu'au 6 septembre 2024.
Quantum-Si (Nasdaq: QSI), ein Unternehmen für Proteinsequenzierung, hat wichtige Führungskräfte ernannt, um seine Entwicklung als führender Anbieter von proteomischen Werkzeugen voranzutreiben. Todd Bennett wird am 16. September 2024 als Chief Commercial Officer zum Unternehmen stoßen und bringt über 30 Jahre Erfahrung in der kommerziellen Führung in den Bereichen Lebenswissenschaften und Diagnostik mit. John Vieceli, Ph.D. wurde zum Chief Product Officer ernannt und wird seine Expertise in der Produktentwicklung und -einführung von führenden Lebenswissenschaftsunternehmen nutzen. Lindsay Thompson wurde zur Chief Human Resources Officer befördert, um ihren Beitrag zur Unternehmenskultur und Talentmanagement anzuerkennen.
Diese strategischen Ernennungen zielen darauf ab, die globale Einführung der Platinum®-Technologie von Quantum-Si zu beschleunigen und die Produktentwicklung und -auslieferung zu verbessern. Das Unternehmen konzentriert sich darauf, alle Aktivitäten von der Produktentwicklung bis zur Kundenlieferung unter der neuen Rolle des Chief Product Officer zu integrieren. Grace Johnston, Ph.D., hat als Chief Commercial Officer zurückgetreten und wird bis zum 6. September 2024 Übergangsunterstützung leisten.
- Appointment of Todd Bennett as Chief Commercial Officer, bringing 30+ years of industry experience
- Promotion of John Vieceli to Chief Product Officer, leveraging his expertise in product development
- Elevation of Lindsay Thompson to Chief Human Resources Officer, strengthening talent management
- Integration of product development to delivery under new Chief Product Officer role
- Recent launch of 2 new sequencing kits and multiple software analysis tools
- Resignation of Grace Johnston as Chief Commercial Officer
“I am pleased to welcome Todd to QSI as we look to leverage his breadth of industry experience to accelerate the global adoption of Platinum®. Todd is a highly regarded commercial leader in our industry and his track record of building high performing commercial teams and driving market adoption of new technologies is perfectly aligned with our needs for the next phase in the commercialization of our Next-Generation Protein Sequencing™ technology,” said Jeff Hawkins, Chief Executive Officer of Quantum-Si.
Mr. Bennett brings over 30 years of commercial leadership experience in life science tools and diagnostics to Quantum-Si. He brings expertise in building and leading teams across sales, marketing, customer service, business development, and strategy. Mr. Bennett has worked at industry leaders such as Luminex, Abbott, Roche and Immucor. Mr. Bennett holds a B.S. degree in Business Administration with an emphasis in finance from the Max M. Fisher College of Business at Ohio State University.
“The implementation of the role of Chief Product Officer will integrate all activities from product development through to production and delivery to customers. We are seeing continued acceleration across all our innovation roadmaps and this new role enhances our ability to continue to deliver new products on time and with the highest quality to our customers. John has been instrumental in the launch of 2 new sequencing kits and multiple new software analysis tools over the past year and his product development and launch experience from leading life sciences companies makes him the ideal person to lead the product organization going forward,” said Mr. Hawkins.
Dr. Vieceli joined Quantum-Si in December of 2022 and prior to that has held leadership roles at top DNA sequencing companies, including Illumina, Omniome, and Pacific Biosciences, focusing on bioinformatics, signal processing, and computer subsystems. At Illumina, he received the 2022 Annual Innovation Award for advancements in signal processing that boosted sequencing accuracy. He is an inventor on over 25 issued patents and pending applications and has authored more than 20 scientific publications. Dr. Vieceli earned his Ph.D. in Theoretical Physical Chemistry from UC Santa Cruz and his B.S. in Biology and Chemistry from Santa Clara University.
“The success of Quantum-Si is driven by the talented people who work here and the Company culture that underpins how we work together every day. Lindsay has been the driving force behind these initiatives for the past four years and this promotion recognizes that contribution and serves as the logical next step in the Company’s growth and development,” said Mr. Hawkins.
Ms.
Finally, Grace Johnston, PhD., has resigned from her role as Chief Commercial Officer. Dr. Johnston will provide transitional support to the Company through September 6, 2024. The Company would like to thank Dr. Johnston for her contributions to Quantum-Si during her tenure.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum™ protein sequencing instrument and kits and the Company’s other products once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company’s most recent Annual Report on Form 10-K, and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827690470/en/
Investor Contact
Doug Farrell, VP, Investor Relations
ir@quantum-si.com
Media Contact
Katherine Atkinson, SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
FAQ
Who is the new Chief Commercial Officer of Quantum-Si (QSI)?
What changes has Quantum-Si (QSI) made to its executive team in 2024?
What is Quantum-Si's (QSI) main product focus?
How many new products has Quantum-Si (QSI) launched recently?
